Details
Stereochemistry | ACHIRAL |
Molecular Formula | C4H3FN2O2 |
Molecular Weight | 130.0772 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CNC(=O)NC1=O
InChI
InChIKey=GHASVSINZRGABV-UHFFFAOYSA-N
InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
Molecular Formula | C4H3FN2O2 |
Molecular Weight | 130.0772 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012209s040lbl.pdf
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012209s040lbl.pdf
Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances from becoming incorporated into DNA during the "S" phase (of the cell cycle), stopping normal development and division. Fluorouracil blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Fluorouracil blocks the incorporation of the thymidine nucleotide into the DNA strand. Fluorouracil is used for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
CNS Activity
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/20080863https://books.google.ru/books?id=_J2ti4EkYpkC&pg=PA1668&lpg=PA1668&dq=FLUOROURACIL retrieved Pharmaceutical Manufacturing Encyclopedia William Andrew Publishing, p.1668
Curator's Comment: Introduced as Efudex by Roche US in 1962
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1952 Sources: http://www.drugbank.ca/drugs/DB00544 |
|||
Target ID: CHEMBL1952 Sources: http://home.intekom.com/pharm/bm_squib/uft.html |
|||
Target ID: CHEMBL614464 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27503679 |
29.5 µM [IC50] | ||
Target ID: CHEMBL390 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19423198 |
16.0 nM [IC50] | ||
Target ID: CHEMBL613860 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26821004 |
43.8 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | UFT E combination granule T100 / T150 Approved Usein the treatment of head and neck cancer, gastric cancer, colorectal cancer, hepatic cancer, gallbladder cancer, bile-duct cancer, pancreatic cancer, lung cancer, breast cancer, bladder cancer, prostatic cancer, or uterine cervical cancer. |
|||
Primary | UFT E combination granule T100 / T150 Approved Usein the treatment of head and neck cancer, gastric cancer, colorectal cancer, hepatic cancer, gallbladder cancer, bile-duct cancer, pancreatic cancer, lung cancer, breast cancer, bladder cancer, prostatic cancer, or uterine cervical cancer. |
|||
Primary | UFT E combination granule T100 / T150 Approved Usein the treatment of head and neck cancer, gastric cancer, colorectal cancer, hepatic cancer, gallbladder cancer, bile-duct cancer, pancreatic cancer, lung cancer, breast cancer, bladder cancer, prostatic cancer, or uterine cervical cancer. |
|||
Primary | UFT E combination granule T100 / T150 Approved Usein the treatment of head and neck cancer, gastric cancer, colorectal cancer, hepatic cancer, gallbladder cancer, bile-duct cancer, pancreatic cancer, lung cancer, breast cancer, bladder cancer, prostatic cancer, or uterine cervical cancer. |
|||
Primary | UFT E combination granule T100 / T150 Approved Usein the treatment of head and neck cancer, gastric cancer, colorectal cancer, hepatic cancer, gallbladder cancer, bile-duct cancer, pancreatic cancer, lung cancer, breast cancer, bladder cancer, prostatic cancer, or uterine cervical cancer. |
|||
Primary | FLUOROURACIL Approved UseFluorouracil is indicated for the treatment of patients with:
Adenocarcinoma of the Colon and Rectum
Adenocarcinoma of the Breast
Gastric Adenocarcinoma
Pancreatic Adenocarcinoma Launch Date1962 |
|||
Primary | FLUOROURACIL Approved UseFluorouracil is indicated for the treatment of patients with:
Adenocarcinoma of the Colon and Rectum
Adenocarcinoma of the Breast
Gastric Adenocarcinoma
Pancreatic Adenocarcinoma Launch Date1962 |
|||
Primary | FLUOROURACIL Approved UseFluorouracil is indicated for the treatment of patients with:
Adenocarcinoma of the Colon and Rectum
Adenocarcinoma of the Breast
Gastric Adenocarcinoma
Pancreatic Adenocarcinoma Launch Date1962 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.49 ng/mL |
1 g 2 times / day steady-state, topical dose: 1 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
FLUOROURACIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
278 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12907286 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUOROURACIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2046.2 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31011915 |
80 mg 2 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered: GIMERACIL |
TEGAFUR plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
22.39 ng × h/mL |
1 g 2 times / day steady-state, topical dose: 1 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
FLUOROURACIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
205 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12907286 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUOROURACIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10786 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31011915 |
80 mg 2 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered: GIMERACIL |
TEGAFUR plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.24 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12907286 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUOROURACIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8.5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31011915 |
80 mg 2 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered: GIMERACIL |
TEGAFUR plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
90% |
FLUOROURACIL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
||
47.7% |
TEGAFUR serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3400 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 3400 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 3400 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
DLT: Ataxia... Other AEs: Anorexia, Nausea... Dose limiting toxicities: Ataxia (grade 3, 4 patients) Other AEs:Anorexia (3 patients) Sources: Nausea (severe, 2 patients) Vomiting (2 patients) Stomatitis (severe, 1 patient) Diarrhea (3 patients) Weakness (1 patient) Hair loss (1 patient) Peeling (1 patient) |
2600 mg/m2 1 times / week multiple, intravenous MTD Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Other AEs: Ataxia, Anorexia... Other AEs: Ataxia (3 patients) Sources: Anorexia (4 patients) Nausea (severe, 2 patients) Vomiting (3 patients) Stomatitis (mild, 3 patients) Diarrhea (2 patients) Weakness (2 patients) Hair loss (2 patients) Loss of eyelashes (1 patient) Peeling (2 patients) Peeling (2 patients) |
2800 mg/m2 1 times / week multiple, intravenous Dose: 2800 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2800 mg/m2, 1 times / week Sources: |
unhealthy, 59 years n = 3 Health Status: unhealthy Age Group: 59 years Sex: M+F Population Size: 3 Sources: |
DLT: Diarrhea... Dose limiting toxicities: Diarrhea (grade 3, 1 patient) Sources: |
3000 mg/m2 1 times / week multiple, intravenous Dose: 3000 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 3000 mg/m2, 1 times / week Sources: |
unhealthy, 59 years n = 14 Health Status: unhealthy Age Group: 59 years Sex: M+F Population Size: 14 Sources: |
DLT: Diarrhea... Dose limiting toxicities: Diarrhea (grade 3-4, 2 patients) Sources: |
3250 mg/m2 1 times / week multiple, intravenous Dose: 3250 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 3250 mg/m2, 1 times / week Sources: |
unhealthy, 59 years n = 9 Health Status: unhealthy Age Group: 59 years Sex: M+F Population Size: 9 Sources: |
DLT: Diarrhea... Dose limiting toxicities: Diarrhea (grade 3-4, 2 patients) Sources: |
0.5 % 1 times / day multiple, topical Recommended Dose: 0.5 %, 1 times / day Route: topical Route: multiple Dose: 0.5 %, 1 times / day Sources: |
unhealthy, adult n = 257 Health Status: unhealthy Condition: actinic keratoses Age Group: adult Sex: M+F Population Size: 257 Sources: |
Disc. AE: Irritation skin... AEs leading to discontinuation/dose reduction: Irritation skin (12%) Sources: |
1250 mg 1 times / 2 days multiple, oral Dose: 1250 mg, 1 times / 2 days Route: oral Route: multiple Dose: 1250 mg, 1 times / 2 days Sources: |
unhealthy, adult n = 7 Health Status: unhealthy Condition: hepatoma Age Group: adult Population Size: 7 Sources: |
|
500 mg single, oral |
unhealthy, adult n = 6 Health Status: unhealthy Condition: breast cancer Age Group: adult Sex: F Population Size: 6 Sources: |
|
5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Other AEs: Anaemia, Angina unstable... Other AEs: Anaemia (serious, 2 patients) Sources: Angina unstable (serious, 5 patients) Arrhythmia (serious, 2 patients) Arteriosclerosis coronary artery (serious, 1 patient) Atrial flutter (serious, 3 patients) Atrial tachycardia (serious, 1 patient) Atrial thrombosis (serious, 1 patient) Cardiac disorder (serious, 1 patient) Cardiac failure congestive (serious, 7 patients) Cardio-respiratory arrest (serious, 2 patients) Coronary artery stenosis (serious, 1 patient) Myocardial ischaemia (serious, 1 patient) Palpitations (serious, 1 patient) Pericarditis (serious, 1 patient) Ventricular tachycardia (serious, 2 patients) Vertigo (serious, 1 patient) Vertigo positional (serious, 1 patient) Disorder vestibular (serious, 1 patient) Goitre (serious, 1 patient) Inappropriate antidiuretic hormone secretion (serious, 1 patient) Abdominal hernia (serious, 1 patient) Colitis ischaemic (serious, 1 patient) Gastritis (serious, 2 patients) Haemorrhoids (serious, 1 patient) Impaired gastric emptying (serious, 1 patient) Hernia inguinal (serious, 1 patient) Intestinal obstruction (serious, 2 patients) Obstruction gastric (serious, 1 patient) Oesophageal obstruction (serious, 1 patient) Pancreatitis (serious, 1 patient) Vomiting (serious, 1 patient) Adhesion (serious, 1 patient) Chest discomfort (serious, 1 patient) Generalised oedema (serious, 1 patient) Non-cardiac chest pain (serious, 3 patients) Cholelithiasis (serious, 2 patients) Hepatitis alcoholic (serious, 1 patient) Arthritis infective (serious, 1 patient) Bacteraemia (serious, 1 patient) Bronchopneumonia (serious, 1 patient) Cholecystitis infective (serious, 1 patient) Clostridium difficile infection (serious, 3 patients) Cystitis (serious, 1 patient) Endocarditis (serious, 1 patient) Incision site cellulitis (serious, 1 patient) Infection (serious, 2 patients) Septic shock (serious, 1 patient) Upper respiratory tract infection (serious, 1 patient) Urinary tract infection (serious, 6 patients) Viral infection (serious, 1 patient) Device toxicity (serious, 1 patient) Fall (serious, 11 patient) Hip fracture (serious, 2 patients) Intentional overdose (serious, 1 patient) Limb injury (serious, 1 patient) Lower limb fracture (serious, 1 patient) Meniscus injury (serious, 2 patients) Periprosthetic fracture (serious, 1 patient) Postoperative fever (serious, 1 patient) Procedural nausea (serious, 1 patient) Procedural pain (serious, 1 patient) Radiation oesophagitis (serious, 1 patient) Road traffic accident (serious, 2 patients) Traumatic haematoma (serious, 1 patient) Vascular bypass dysfunction (serious, 1 patient) Blood glucose increased (serious, 1 patient) Electrocardiogram abnormal (serious, 1 patient) Haemoglobin decreased (serious, 1 patient) International normalised ratio increased (serious, 2 patients) White blood cell count increased (serious, 1 patient) Dehydration (serious, 5 patients) Diabetes mellitus inadequate control (serious, 2 patients) Failure to thrive (serious, 3 patients) Hyperglycaemia (serious, 2 patients) Hyponatraemia (serious, 3 patients) Iron deficiency (serious, 1 patient) Arthralgia (serious, 3 patients) Bursa disorder (serious, 1 patient) Exostosis (serious, 1 patient) Muscular weakness (serious, 1 patient) Osteoarthritis (serious, 10 patients) Tendonitis (serious, 1 patient) Basal cell carcinoma (serious, 1 patient) Benign salivary gland neoplasm (serious, 1 patient) Brain neoplasm (serious, 2 patients) Colorectal cancer (serious, 1 patient) Diffuse large B-cell lymphoma stage IV (serious, 1 patient) Haemangioma (serious, 1 patient) Lung neoplasm malignant (serious, 4 patients) Malignant melanoma (serious, 3 patients) Metastases to central nervous system (serious, 1 patient) Metastatic squamous cell carcinoma (serious, 1 patient) Neuroendocrine carcinoma (serious, 1 patient) Prostate cancer (serious, 5 patients) Prostate cancer recurrent (serious, 1 patient) Renal cancer (serious, 2 patients) Renal cancer metastatic (serious, 1 patient) Renal cell carcinoma (serious, 1 patient) Salivary gland cancer (serious, 1 patient) Squamous cell carcinoma (serious, 2 patients) Basilar artery stenosis (serious, 1 patient) Cognitive disorder (serious, 1 patient) Dementia (serious, 4 patients) Epilepsy (serious, 1 patient) Headache (serious, 1 patient) Hypoaesthesia (serious, 1 patient) Parkinson's disease (serious, 2 patients) Haemorrhage subarachnoid (serious, 1 patient) Transient ischaemic attack (serious, 4 patients) Transient ischaemic attack (serious, 4 patients) Dementia vascular (serious, 1 patient) Alcohol abuse (serious, 2 patients) Binge drinking (serious, 1 patient) Completed suicide (serious, 1 patient) Confusional state (serious, 1 patient) Delirium tremens (serious, 1 patient) Depression (serious, 3 patients) Mental disorder (serious, 1 patient) Mental status changes (serious, 2 patients) Post-traumatic stress disorder (serious, 1 patient) Suicidal behaviour (serious, 1 patient) Suicidal ideation (serious, 3 patients) Hydronephrosis (serious, 2 patients) Nephropathy (serious, 1 patient) Renal failure chronic (serious, 1 patient) Erectile dysfunction (serious, 1 patient) Prostatic haemorrhage (serious, 1 patient) Prostatitis (serious, 1 patient) Chronic obstructive pulmonary disease (serious, 9 patients) Dyspnoea (serious, 2 patients) Dyspnoea exertional (serious, 1 patient) Haemoptysis (serious, 1 patient) Pleural effusion (serious, 1 patient) Pulmonary embolism (serious, 3 patients) Respiratory failure (serious, 1 patient) Rash (serious, 1 patient) Angioplasty (serious, 1 patient) Cholecystectomy (serious, 1 patient) Coronary angioplasty (serious, 1 patient) Elective procedure (serious, 1 patient) Hip arthroplasty (serious, 1 patient) Knee arthroplasty (serious, 1 patient) Medical device removal (serious, 1 patient) Oesophagogastric fundoplasty (serious, 1 patient) Parotidectomy (serious, 1 patient) Wound treatment (serious, 1 patient) Aortic aneurysm (serious, 2 patients) Aortic occlusion (serious, 1 patient) Arterial occlusive disease (serious, 1 patient) Femoral artery occlusion (serious, 1 patient) Labile hypertension (serious, 1 patient) Orthostatic hypotension (serious, 2 patients) Disorder peripheral vascular (serious, 1 patient) Lymphadenopathy (below serious, 1 patient) Vertigo (below serious, 1 patient) Adrenal mass (below serious, 1 patient) Eye haemorrhage (below serious, 1 patient) Eye irritation (below serious, 3 patients) Eye pain (below serious, 2 patients) Eye pruritus (below serious, 1 patient) Eye swelling (below serious, 4 patients) Photophobia (below serious, 1 patient) Visual acuity reduced (below serious, 1 patient) Abdominal pain upper (below serious, 2 patients) Cheilitis (below serious, 1 patient) Diarrhoea (below serious, 3 patients) Diverticulum (below serious, 1 patient) Dyspepsia (below serious, 1 patient) Gastrooesophageal reflux disease (below serious, 1 patient) Gingival pain (below serious, 1 patient) Nausea (below serious, 5 patients) Fatigue (below serious, 3 patients) Feeling of body temperature change (below serious, 1 patient) Hernia (below serious, 1 patient) Local swelling (below serious, 1 patient) Malaise (below serious, 1 patient) Pain (below serious, 11 patient) Syringe issue (below serious, 1 patient) Temperature intolerance (below serious, 1 patient) Tenderness (below serious, 2 patients) Vessel puncture site haematoma (below serious, 1 patient) Hypersensitivity (below serious, 1 patient) Seasonal allergy (below serious, 1 patient) Bronchitis (below serious, 4 patients) Cellulitis (below serious, 1 patient) Folliculitis (below serious, 1 patient) Fungal infection (below serious, 1 patient) Herpes zoster (below serious, 2 patients) Infection (below serious, 2 patients) Influenza (below serious, 1 patient) Nasopharyngitis (below serious, 5 patients) Oral herpes (below serious, 1 patient) Pneumonia (below serious, 2 patients) Accidental exposure to product (below serious, 1 patient) Arthropod sting (below serious, 1 patient) Fall (below serious, 5 patients) Laceration (below serious, 1 patient) Muscle rupture (below serious, 1 patient) Body temperature increased (below serious, 1 patient) Emergency care examination (below serious, 1 patient) Gout (below serious, 1 patient) Arthralgia (below serious, 1 patient) Back pain (below serious, 3 patients) Foot deformity (below serious, 1 patient) Musculoskeletal pain (below serious, 1 patient) Neck pain (below serious, 1 patient) Pain in extremity (below serious, 1 patient) Polymyalgia rheumatica (below serious, 1 patient) Basal cell carcinoma (below serious, 1 patient) Haemangioma (below serious, 1 patient) Transitional cell carcinoma (below serious, 1 patient) Burning sensation (below serious, 1 patient) Dizziness (below serious, 4 patients) Headache (below serious, 5 patients) Hypoaesthesia (below serious, 2 patients) Syncope (below serious, 1 patient) Tunnel vision (below serious, 1 patient) Abnormal dreams (below serious, 1 patient) Anxiety (below serious, 1 patient) Psychotic disorder (below serious, 1 patient) Sleep disorder (below serious, 22 patients) Dysuria (below serious, 1 patient) Haemorrhage urinary tract (below serious, 1 patient) Pollakiuria (below serious, 1 patient) Chronic obstructive pulmonary disease (below serious, 1 patient) Nasal congestion (below serious, 1 patient) Productive cough (below serious, 1 patient) Pulmonary mass (below serious, 1 patient) Rhinorrhoea (below serious, 1 patient) Sinus disorder (below serious, 1 patient) Acne (below serious, 5 patients) Blister (below serious, 2 patients) Blood blister (below serious, 1 patient) Decubitus ulcer (below serious, 1 patient) Dermatitis (below serious, 447 patients) Dermatitis allergic (below serious, 1 patient) Hyperhidrosis (below serious, 2 patients) Photosensitivity reaction (below serious, 5 patients) Post inflammatory pigmentation change (below serious, 1 patient) Scab (below serious, 1 patient) Seborrhoea (below serious, 1 patient) Dermatitis seborrhoeic (below serious, 2 patients) Skin discomfort (below serious, 1 patient) Skin haemorrhage (below serious, 3 patients) Skin tightness (below serious, 1 patient) Skin ulcer (below serious, 1 patient) Urticaria (below serious, 1 patient) Oral surgery (below serious, 1 patient) Wound drainage (below serious, 1 patient) Haemorrhage (below serious, 7 patients) Temporal arteritis (below serious, 1 patient) |
111.6 mg/m2 1 times / day steady, oral RP2D Dose: 111.6 mg/m2, 1 times / day Route: oral Route: steady Dose: 111.6 mg/m2, 1 times / day Co-administed with:: uracil(248.4 mg/m2) Sources: |
unhealthy, 54 years n = 6 Health Status: unhealthy Condition: carcinoma Age Group: 54 years Sex: M+F Population Size: 6 Sources: |
Other AEs: Fatigue, Nausea... Other AEs: Fatigue (grade 1-2, 3 patients) Sources: Nausea (grade 1-2, 2 patients) |
248 mg/m2 1 times / day steady, oral RP2D Dose: 248 mg/m2, 1 times / day Route: oral Route: steady Dose: 248 mg/m2, 1 times / day Co-administed with:: uracil(552 mg/m2) Sources: |
unhealthy, 59 years n = 8 Health Status: unhealthy Condition: carcinoma Age Group: 59 years Sex: M+F Population Size: 8 Sources: |
Other AEs: Granulocytopenia, Nausea... Other AEs: Granulocytopenia (grade 4, 1 patient) Sources: Nausea (grade 3, 1 patient) Thrombocytopenia (grade 3, 1 patient) Vomiting (grade 1-2, 5 patients) Fatigue (grade 1-2, 4 patients) Diarrhoea (grade 1-2, 4 patients) |
139.5 mg/m2 1 times / day steady, oral Highest studied dose Dose: 139.5 mg/m2, 1 times / day Route: oral Route: steady Dose: 139.5 mg/m2, 1 times / day Co-administed with:: uracil(310.5 mg/m2) Sources: |
unhealthy n = 6 |
DLT: Diarrhea... Dose limiting toxicities: Diarrhea (grade 3-4, 3 patients) Sources: |
279 mg/m2 1 times / day steady, oral Highest studied dose Dose: 279 mg/m2, 1 times / day Route: oral Route: steady Dose: 279 mg/m2, 1 times / day Co-administed with:: uracil(621 mg/m2) Sources: |
unhealthy n = 5 |
DLT: Granulocytopenia... Dose limiting toxicities: Granulocytopenia (grade 4, 4 patients) Sources: |
124 mg/m2 1 times / day steady, oral Dose: 124 mg/m2, 1 times / day Route: oral Route: steady Dose: 124 mg/m2, 1 times / day Co-administed with:: uracil(276 mg/m2) Sources: |
unhealthy n = 8 |
DLT: Diarrhea... Dose limiting toxicities: Diarrhea (grade 3-4, 3 patients) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hair loss | 1 patient | 3400 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 3400 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 3400 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Peeling | 1 patient | 3400 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 3400 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 3400 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Weakness | 1 patient | 3400 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 3400 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 3400 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Vomiting | 2 patients | 3400 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 3400 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 3400 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Anorexia | 3 patients | 3400 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 3400 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 3400 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Diarrhea | 3 patients | 3400 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 3400 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 3400 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Ataxia | grade 3, 4 patients DLT, Disc. AE |
3400 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 3400 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 3400 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Stomatitis | severe, 1 patient | 3400 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 3400 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 3400 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Nausea | severe, 2 patients | 3400 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 3400 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 3400 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Loss of eyelashes | 1 patient | 2600 mg/m2 1 times / week multiple, intravenous MTD Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Diarrhea | 2 patients | 2600 mg/m2 1 times / week multiple, intravenous MTD Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Hair loss | 2 patients | 2600 mg/m2 1 times / week multiple, intravenous MTD Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Peeling | 2 patients | 2600 mg/m2 1 times / week multiple, intravenous MTD Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Peeling | 2 patients | 2600 mg/m2 1 times / week multiple, intravenous MTD Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Weakness | 2 patients | 2600 mg/m2 1 times / week multiple, intravenous MTD Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Ataxia | 3 patients | 2600 mg/m2 1 times / week multiple, intravenous MTD Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Vomiting | 3 patients | 2600 mg/m2 1 times / week multiple, intravenous MTD Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Anorexia | 4 patients | 2600 mg/m2 1 times / week multiple, intravenous MTD Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Stomatitis | mild, 3 patients | 2600 mg/m2 1 times / week multiple, intravenous MTD Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Nausea | severe, 2 patients | 2600 mg/m2 1 times / week multiple, intravenous MTD Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: |
unhealthy, 54 years (range: 24-78 years) n = 8 Health Status: unhealthy Condition: Advanced Pancreatic Cancer| Colorectal Cancer Age Group: 54 years (range: 24-78 years) Sex: M+F Population Size: 8 Sources: |
Diarrhea | grade 3, 1 patient DLT |
2800 mg/m2 1 times / week multiple, intravenous Dose: 2800 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2800 mg/m2, 1 times / week Sources: |
unhealthy, 59 years n = 3 Health Status: unhealthy Age Group: 59 years Sex: M+F Population Size: 3 Sources: |
Diarrhea | grade 3-4, 2 patients DLT |
3000 mg/m2 1 times / week multiple, intravenous Dose: 3000 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 3000 mg/m2, 1 times / week Sources: |
unhealthy, 59 years n = 14 Health Status: unhealthy Age Group: 59 years Sex: M+F Population Size: 14 Sources: |
Diarrhea | grade 3-4, 2 patients DLT |
3250 mg/m2 1 times / week multiple, intravenous Dose: 3250 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 3250 mg/m2, 1 times / week Sources: |
unhealthy, 59 years n = 9 Health Status: unhealthy Age Group: 59 years Sex: M+F Population Size: 9 Sources: |
Irritation skin | 12% Disc. AE |
0.5 % 1 times / day multiple, topical Recommended Dose: 0.5 %, 1 times / day Route: topical Route: multiple Dose: 0.5 %, 1 times / day Sources: |
unhealthy, adult n = 257 Health Status: unhealthy Condition: actinic keratoses Age Group: adult Sex: M+F Population Size: 257 Sources: |
Abnormal dreams | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Accidental exposure to product | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Adrenal mass | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Anxiety | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Arthralgia | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Arthropod sting | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Basal cell carcinoma | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Blood blister | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Body temperature increased | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Burning sensation | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Cellulitis | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Cheilitis | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Chronic obstructive pulmonary disease | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Decubitus ulcer | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Dermatitis allergic | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Diverticulum | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Dyspepsia | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Dysuria | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Emergency care examination | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Eye haemorrhage | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Eye pruritus | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Feeling of body temperature change | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Folliculitis | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Foot deformity | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Fungal infection | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Gastrooesophageal reflux disease | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Gingival pain | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Gout | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Haemangioma | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Haemorrhage urinary tract | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Hernia | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Hypersensitivity | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Influenza | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Laceration | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Local swelling | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Lymphadenopathy | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Malaise | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Muscle rupture | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Musculoskeletal pain | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Nasal congestion | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Neck pain | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Oral herpes | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Oral surgery | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Pain in extremity | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Photophobia | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Pollakiuria | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Polymyalgia rheumatica | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Post inflammatory pigmentation change | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Productive cough | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Psychotic disorder | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Pulmonary mass | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Rhinorrhoea | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Scab | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Seasonal allergy | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Seborrhoea | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Sinus disorder | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Skin discomfort | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Skin tightness | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Skin ulcer | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Syncope | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Syringe issue | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Temperature intolerance | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Temporal arteritis | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Transitional cell carcinoma | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Tunnel vision | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Urticaria | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Vertigo | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Vessel puncture site haematoma | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Visual acuity reduced | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Wound drainage | below serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Pain | below serious, 11 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Abdominal pain upper | below serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Blister | below serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Dermatitis seborrhoeic | below serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Eye pain | below serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Herpes zoster | below serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Hyperhidrosis | below serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Hypoaesthesia | below serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Infection | below serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Pneumonia | below serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Tenderness | below serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Sleep disorder | below serious, 22 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Back pain | below serious, 3 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Diarrhoea | below serious, 3 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Eye irritation | below serious, 3 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Fatigue | below serious, 3 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Skin haemorrhage | below serious, 3 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Bronchitis | below serious, 4 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Dizziness | below serious, 4 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Eye swelling | below serious, 4 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Dermatitis | below serious, 447 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Acne | below serious, 5 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Fall | below serious, 5 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Headache | below serious, 5 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Nasopharyngitis | below serious, 5 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Nausea | below serious, 5 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Photosensitivity reaction | below serious, 5 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Haemorrhage | below serious, 7 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Abdominal hernia | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Adhesion | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Angioplasty | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Aortic occlusion | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Arterial occlusive disease | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Arteriosclerosis coronary artery | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Arthritis infective | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Atrial tachycardia | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Atrial thrombosis | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Bacteraemia | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Basal cell carcinoma | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Basilar artery stenosis | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Benign salivary gland neoplasm | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Binge drinking | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Blood glucose increased | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Bronchopneumonia | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Bursa disorder | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Cardiac disorder | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Chest discomfort | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Cholecystectomy | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Cholecystitis infective | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Cognitive disorder | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Colitis ischaemic | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Colorectal cancer | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Completed suicide | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Confusional state | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Coronary angioplasty | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Coronary artery stenosis | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Cystitis | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Delirium tremens | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Dementia vascular | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Device toxicity | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Diffuse large B-cell lymphoma stage IV | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Disorder peripheral vascular | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Disorder vestibular | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Dyspnoea exertional | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Elective procedure | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Electrocardiogram abnormal | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Endocarditis | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Epilepsy | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Erectile dysfunction | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Exostosis | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Femoral artery occlusion | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Generalised oedema | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Goitre | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Haemangioma | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Haemoglobin decreased | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Haemoptysis | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Haemorrhage subarachnoid | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Haemorrhoids | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Headache | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Hepatitis alcoholic | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Hernia inguinal | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Hip arthroplasty | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Hypoaesthesia | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Impaired gastric emptying | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Inappropriate antidiuretic hormone secretion | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Incision site cellulitis | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Intentional overdose | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Iron deficiency | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Knee arthroplasty | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Labile hypertension | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Limb injury | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Lower limb fracture | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Medical device removal | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Mental disorder | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Metastases to central nervous system | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Metastatic squamous cell carcinoma | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Muscular weakness | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Myocardial ischaemia | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Nephropathy | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Neuroendocrine carcinoma | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Obstruction gastric | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Oesophageal obstruction | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Oesophagogastric fundoplasty | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Palpitations | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Pancreatitis | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Parotidectomy | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Pericarditis | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Periprosthetic fracture | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Pleural effusion | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Post-traumatic stress disorder | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Postoperative fever | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Procedural nausea | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Procedural pain | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Prostate cancer recurrent | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Prostatic haemorrhage | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Prostatitis | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Radiation oesophagitis | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Rash | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Renal cancer metastatic | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Renal cell carcinoma | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Renal failure chronic | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Respiratory failure | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Salivary gland cancer | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Septic shock | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Suicidal behaviour | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Tendonitis | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Traumatic haematoma | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Upper respiratory tract infection | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Vascular bypass dysfunction | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Vertigo positional | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Vertigo | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Viral infection | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Vomiting | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
White blood cell count increased | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Wound treatment | serious, 1 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Osteoarthritis | serious, 10 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Fall | serious, 11 patient | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Alcohol abuse | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Anaemia | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Aortic aneurysm | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Arrhythmia | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Brain neoplasm | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Cardio-respiratory arrest | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Cholelithiasis | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Diabetes mellitus inadequate control | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Dyspnoea | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Gastritis | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Hip fracture | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Hydronephrosis | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Hyperglycaemia | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Infection | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
International normalised ratio increased | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Intestinal obstruction | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Meniscus injury | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Mental status changes | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Orthostatic hypotension | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Parkinson's disease | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Renal cancer | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Road traffic accident | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Squamous cell carcinoma | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Ventricular tachycardia | serious, 2 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Arthralgia | serious, 3 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Atrial flutter | serious, 3 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Clostridium difficile infection | serious, 3 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Depression | serious, 3 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Failure to thrive | serious, 3 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Hyponatraemia | serious, 3 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Malignant melanoma | serious, 3 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Non-cardiac chest pain | serious, 3 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Pulmonary embolism | serious, 3 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Suicidal ideation | serious, 3 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Dementia | serious, 4 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Lung neoplasm malignant | serious, 4 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Transient ischaemic attack | serious, 4 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Transient ischaemic attack | serious, 4 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Angina unstable | serious, 5 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Dehydration | serious, 5 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Prostate cancer | serious, 5 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Urinary tract infection | serious, 6 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Cardiac failure congestive | serious, 7 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Chronic obstructive pulmonary disease | serious, 9 patients | 5 % 2 times / day steady, topical Dose: 5 %, 2 times / day Route: topical Route: steady Dose: 5 %, 2 times / day Sources: |
unhealthy n = 468 Health Status: unhealthy Condition: Keratinocyte carcinoma Population Size: 468 Sources: |
Nausea | grade 1-2, 2 patients | 111.6 mg/m2 1 times / day steady, oral RP2D Dose: 111.6 mg/m2, 1 times / day Route: oral Route: steady Dose: 111.6 mg/m2, 1 times / day Co-administed with:: uracil(248.4 mg/m2) Sources: |
unhealthy, 54 years n = 6 Health Status: unhealthy Condition: carcinoma Age Group: 54 years Sex: M+F Population Size: 6 Sources: |
Fatigue | grade 1-2, 3 patients | 111.6 mg/m2 1 times / day steady, oral RP2D Dose: 111.6 mg/m2, 1 times / day Route: oral Route: steady Dose: 111.6 mg/m2, 1 times / day Co-administed with:: uracil(248.4 mg/m2) Sources: |
unhealthy, 54 years n = 6 Health Status: unhealthy Condition: carcinoma Age Group: 54 years Sex: M+F Population Size: 6 Sources: |
Diarrhoea | grade 1-2, 4 patients | 248 mg/m2 1 times / day steady, oral RP2D Dose: 248 mg/m2, 1 times / day Route: oral Route: steady Dose: 248 mg/m2, 1 times / day Co-administed with:: uracil(552 mg/m2) Sources: |
unhealthy, 59 years n = 8 Health Status: unhealthy Condition: carcinoma Age Group: 59 years Sex: M+F Population Size: 8 Sources: |
Fatigue | grade 1-2, 4 patients | 248 mg/m2 1 times / day steady, oral RP2D Dose: 248 mg/m2, 1 times / day Route: oral Route: steady Dose: 248 mg/m2, 1 times / day Co-administed with:: uracil(552 mg/m2) Sources: |
unhealthy, 59 years n = 8 Health Status: unhealthy Condition: carcinoma Age Group: 59 years Sex: M+F Population Size: 8 Sources: |
Vomiting | grade 1-2, 5 patients | 248 mg/m2 1 times / day steady, oral RP2D Dose: 248 mg/m2, 1 times / day Route: oral Route: steady Dose: 248 mg/m2, 1 times / day Co-administed with:: uracil(552 mg/m2) Sources: |
unhealthy, 59 years n = 8 Health Status: unhealthy Condition: carcinoma Age Group: 59 years Sex: M+F Population Size: 8 Sources: |
Nausea | grade 3, 1 patient | 248 mg/m2 1 times / day steady, oral RP2D Dose: 248 mg/m2, 1 times / day Route: oral Route: steady Dose: 248 mg/m2, 1 times / day Co-administed with:: uracil(552 mg/m2) Sources: |
unhealthy, 59 years n = 8 Health Status: unhealthy Condition: carcinoma Age Group: 59 years Sex: M+F Population Size: 8 Sources: |
Thrombocytopenia | grade 3, 1 patient | 248 mg/m2 1 times / day steady, oral RP2D Dose: 248 mg/m2, 1 times / day Route: oral Route: steady Dose: 248 mg/m2, 1 times / day Co-administed with:: uracil(552 mg/m2) Sources: |
unhealthy, 59 years n = 8 Health Status: unhealthy Condition: carcinoma Age Group: 59 years Sex: M+F Population Size: 8 Sources: |
Granulocytopenia | grade 4, 1 patient | 248 mg/m2 1 times / day steady, oral RP2D Dose: 248 mg/m2, 1 times / day Route: oral Route: steady Dose: 248 mg/m2, 1 times / day Co-administed with:: uracil(552 mg/m2) Sources: |
unhealthy, 59 years n = 8 Health Status: unhealthy Condition: carcinoma Age Group: 59 years Sex: M+F Population Size: 8 Sources: |
Diarrhea | grade 3-4, 3 patients DLT |
139.5 mg/m2 1 times / day steady, oral Highest studied dose Dose: 139.5 mg/m2, 1 times / day Route: oral Route: steady Dose: 139.5 mg/m2, 1 times / day Co-administed with:: uracil(310.5 mg/m2) Sources: |
unhealthy n = 6 |
Granulocytopenia | grade 4, 4 patients DLT |
279 mg/m2 1 times / day steady, oral Highest studied dose Dose: 279 mg/m2, 1 times / day Route: oral Route: steady Dose: 279 mg/m2, 1 times / day Co-administed with:: uracil(621 mg/m2) Sources: |
unhealthy n = 5 |
Diarrhea | grade 3-4, 3 patients DLT |
124 mg/m2 1 times / day steady, oral Dose: 124 mg/m2, 1 times / day Route: oral Route: steady Dose: 124 mg/m2, 1 times / day Co-administed with:: uracil(276 mg/m2) Sources: |
unhealthy n = 8 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 3110 uM] | ||||
no | ||||
Sources: https://jpet.aspetjournals.org/content/297/3/1166 Page: - |
no | |||
no | ||||
Sources: https://jpet.aspetjournals.org/content/297/3/1166 Page: - |
no | |||
no | ||||
Sources: https://jpet.aspetjournals.org/content/297/3/1166 Page: - |
no | |||
no | ||||
Sources: https://jpet.aspetjournals.org/content/297/3/1166 Page: - |
no | |||
no | ||||
Sources: https://jpet.aspetjournals.org/content/297/3/1166 Page: - |
no | |||
no | ||||
Sources: https://jpet.aspetjournals.org/content/297/3/1166 Page: - |
no | |||
no | ||||
Sources: https://jpet.aspetjournals.org/content/297/3/1166 Page: - |
no | |||
weak | ||||
weak | ||||
weak | ||||
Page: - |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/11106261/ Page: - |
major | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11106261/ Page: - |
major | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11106261/ Page: - |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11106261/ Page: - |
minor | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11106261/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11106261/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11106261/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11106261/ Page: - |
no | |||
Sources: https://europepmc.org/article/med/11095583 Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11106261/ Page: - |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Clinical evaluation of ftorafur (pyrimidine-deoxyribose n1-2'-furanidyl-5-fluorouracil). | 1976 May |
|
Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers. | 1977 Dec |
|
[Experience of a combination chemotherapy consisting of 5-FU, MMC, and FT-207--side effects against kidney]. | 1983 Sep |
|
[A case of variant angina induced by 5-fluorouracil and Tegafur]. | 1988 Nov |
|
[Macrocytic anemia as a possible adverse effect of fluoropyrimidines]. | 1990 Aug |
|
Hypercoagulopathy induced by chemotherapy in a patient with lung cancer. A possible role for a factor with thrombosis-inducing activity (TIA). | 1992 Jan |
|
Leukoencephalopathy induced by chemotherapy with tegafur, a 5-fluorouracil derivative. | 1998 Nov |
|
Analysis of uracil DNA glycosylase in human colorectal cancer. | 2001 Feb |
|
Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer. | 2001 Feb |
|
Effect of a mutant form of IkappaB-alpha on 5-fluorouracil-induced apoptosis in transformed human salivary gland cells. | 2001 Feb |
|
Thrombopoietin signaling is required for in vivo expansion of IL-11--responsive hematopoietic progenitor cells in the steady state. | 2001 Feb |
|
In vivo evaluation of a novel antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation. | 2001 Feb 1 |
|
E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. | 2001 Feb 10 |
|
Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. | 2001 Feb 2 |
|
Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. | 2001 Jan |
|
Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. | 2001 Jan |
|
Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer. | 2001 Jan |
|
Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. | 2001 Jan 1 |
|
Comparison of the malignant phenotype and genotype of the human androgen-independent cell line DU 145 and a subline derived from metastasis after orthotopic implantation in nude mice. | 2001 Jan 15 |
|
Therapeutic approaches to metastasis confined to the liver. | 2001 Mar |
|
Determinants of prognosis and response to therapy in colorectal cancer. | 2001 Mar |
|
Adjuvant chemotherapy for colon cancer. | 2001 Mar |
|
Antioxidants enhance the susceptibility of colon carcinoma cells to 5-fluorouracil by augmenting the induction of the bax protein. | 2001 Mar 10 |
|
Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur. | 2001 May |
|
Characterization of a genotype previously designated as CYP2A6 D-type: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese. | 2002 Aug |
|
The prodrugs of 5-fluorouracil. | 2002 Mar |
|
Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres. | 2003 Apr |
|
Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma. | 2003 Aug 18 |
|
Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. | 2003 Sep 1 |
|
Phase I/II study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small-cell lung cancer. | 2003 Sep 1 |
|
Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. | 2004 Aug 16 |
|
Dependence of chemotherapy response on p53 mutation status in a panel of human cancer lines maintained in nude mice. | 2004 Jun |
|
Severe colitis after administration of UFT chemotherapy for temporal bone carcinoma. | 2004 Mar |
|
Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs. | 2004 May |
|
Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. | 2004 Sep |
|
New medium oxacyclic O,N-acetals and related open analogues: biological activities. | 2005 |
|
Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer. | 2005 Apr 1 |
|
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. | 2007 Aug 6 |
|
[Study on antitumor effect and its toxicity of Ipomoea Batatas Poir Cv anthocyanins]. | 2008 Jul |
|
Role of oxaliplatin in the treatment of colorectal cancer. | 2009 Feb |
|
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. | 2009 Jan |
|
Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. | 2009 Oct |
|
Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer. | 2010 Jan |
|
Formulation and physicochemical characterization of poly(epsilon-caprolactone) nanoparticles loaded with ftorafur and diclofenac sodium. | 2010 Jan 1 |
|
[Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine]. | 2010 Jan-Feb |
|
A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. | 2010 Mar 15 |
|
A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. | 2010 May 15 |
|
Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+. | 2010 Sep 13 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
Zebrafish (Danio rerio) embryos as a model for testing proteratogens. | 2011 Mar 15 |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.otsuka.tw/photo/product/sheet_pdf_60.pdf
Curator's Comment: Fluorouracil is recommended for administration either as an intravenous bolus or as an intravenous infusion, but may also be used topically http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
General dosage regimen (for adults): UFT (Tegafur, urac) is administered 1.5-3g (equivalent to 300-600 mg of Tegafur) daily in two to three divided doses. For uterine cervical cancer, UFT is administered 3g (equivalent to 600mg of Tegafur) daily in two to three divided doses
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:09:22 GMT 2023
by
admin
on
Fri Dec 15 15:09:22 GMT 2023
|
Record UNII |
U3P01618RT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
NBK548781
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
||
|
NCI_THESAURUS |
C1557
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
||
|
WHO-ATC |
L01BC02
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.2
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
||
|
IARC | 5-Fluorouracil | ||
|
FDA ORPHAN DRUG |
40589
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
13.4
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
||
|
WHO-ATC |
L01BC52
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
||
|
FDA ORPHAN DRUG |
42289
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
||
|
WHO-VATC |
QL01BC02
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
||
|
NDF-RT |
N0000000233
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
||
|
NCI_THESAURUS |
C2021
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
||
|
WHO-VATC |
QL01BC52
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/00/004
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
||
|
FDA ORPHAN DRUG |
32088
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
||
|
NDF-RT |
N0000175595
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
||
|
FDA ORPHAN DRUG |
131799
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
19893
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
m5483
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | Merck Index | ||
|
U3P01618RT
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
FLUOROURACIL
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
200-085-6
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
FLUOROURACIL
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | Description: A white or almost white, crystalline powder. Solubility: Sparingly soluble in water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Cytotoxic drug. Storage: Fluorouracil should be kept in a tightly closed container, protected from light. Additional information: Fluorouracil melts at about 282?C with decomposition. CAUTION: Fluorouracil must be handled with care, avoiding contact with the skin and inhalation of airborne particles. Definition: Fluorouracil contains not less than 98.5% and not more than 101.0% of C4H3FN2O2, calculated with reference to the dried substance. | ||
|
D005472
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
26
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
CHEMBL185
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
C505
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
SUB07721MIG
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
3385
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
DTXSID2020634
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
1279000
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
46345
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
U3P01618RT
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
3228
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
4789
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
4492
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | RxNorm | ||
|
100000091592
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
Fluorouracil
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
51-21-8
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
1421
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY | |||
|
DB00544
Created by
admin on Fri Dec 15 15:09:22 GMT 2023 , Edited by admin on Fri Dec 15 15:09:22 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE |
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
TARGET -> INHIBITOR | |||
|
TRANSPORTER -> SUBSTRATE |
Down-regulation of ABCB5αresulted in a gain of drug sensitivity to camptothecin 10-OH, 5-fluorouracil, and mitoxantrone.
|
||
|
EXCRETED UNCHANGED |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE ACTIVE -> PRODRUG | |||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
METABOLITE INACTIVE -> PARENT | |||
|
PRODRUG -> METABOLITE ACTIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|